Article

Study: modulator in wound healing with trabeculectomy

Dorado, Puerto Rico-After positive results from a European clinical trial showed transforming growth factor-b2 (TGF-b2) mono clonal antibody was effective in delaying wound healing after first-time trabeculectomy, U.S. investigators are undertaking a multicenter clinical trial to compare the new agent with 5-fluorouracil (5-FU), reported Marshall N. Cyrlin, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
Related Content
Zeiss Medical Technology gains NMPA approval for ILM-Blue in China
April 1st 2025

Zeiss Medical Technology gains NMPA approval for ILM-Blue in China

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

OSRX expands medication sizes and adds direct-to-patient post-op kits
March 19th 2025

OSRX expands medication sizes and adds direct-to-patient post-op kits

Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures
March 29th 2024

(EyePod) From idea to impact: Navigating ophthalmic innovation

Optimization of IOL selection and techniques enhances cataract surgery outcomes
February 26th 2025

Optimization of IOL selection and techniques enhances cataract surgery outcomes

Ophthalmology sees AI-powered impact on cataract and diabetic eye disease
February 25th 2025

Ophthalmology sees AI-powered impact on cataract and diabetic eye disease

© 2025 MJH Life Sciences

All rights reserved.